Login and fund life
A novel treatment for hundreds of thousands of patients with advanced heart failure admitted to hospitals worldwide because of a fluid retention problem. Used by patients at home, the device offers convenience and safer removal of fluid at a lower cost.
Team seems to posses the necessary skills and knowledge to achieve the presented goals.
The three people team quoted in the company presentation have large experience in commercialization in the medical device field. The approach is completeley different to the solutions alreday in the market or in development by others. It would be disrupting. The project is using established technology to address important health problem. The way in which the problem is tackled is innovative.
The idea seems elegant and straightforward. It seems they are solving a problem in a very innovative way with no similar approach of other competitors.
The expertise of the team is overwhelming.
It is a brilliant idea.
Every year hundreds of thousands of patients with advanced heart failure are admitted to hospitals worldwide because of a fluid retention problem. Their bodies swell up leading to problems with moving and breathing and they need to get large doses of intravenous diuretics to get rid of that fluid and the associated problems. This requires costly hospitalization and carries significant risks of complications such as acute kidney injury. It is also very inconvenient for the patient.
Several attempts to solve this problem have been tried and have been unsuccessful. Renephra, the University of Manchester and Manchester Foundation Trust spin out company, is developing a gentler, safer treatment that can be delivered at home offering patients better quality of life and reducing hospital admissions and costs to healthcare providers.
Renephra’s patented Transdermal Fluid Removal (TFR) device removes excess fluid from the body through the skin. It uses microneedles to access the fluid located in the skin and negative pressure to remove it. Proof of concept studies demonstrated that in a suitable patient, clinically relevant fluid volumes can be removed with TFR approach.
Idalia has many years of international commercial experience within the pharmaceutical sector followed by several years of research commercialisation supporting university spin-out ventures. She is the founder and director of ID Venture Ltd which works with university incubators and academic founders to develop innovations and technologies into products and services with real commercial prospects. Previously she spent 10 years with AstraZeneca where she held various roles including Regional Marketing Manager for Central and Eastern Europe. Idalia also holds a degree in medicine and an MBA with merit from Manchester Business School.
Founder, Global Medical Director, and Chairman of Synexus. Chairman eLucid. Chairman Beamline. Founder and Chairman of Chorley Medical Services (1982-88). Chairman of Healthcare at Home Advisory board (2010-2012). Extensive experience in feasibility and delivery of clinical trials in multiple therapy areas. MBE for services to Medical Research.
Duncan has worked in the medical devices industry for over 19 years, primarily leading the design and development of implantable medical devices. He has worked in startups and small companies in close partnership with multinational corporations, he has gained a deep understanding of the process of taking a medical device from concept to market. He has particular expertise in quality systems and design control for the EU, US and Japanese markets.
Sandip is a Consultant Nephrologist at Manchester Royal Infirmary where he leads the largest home hemodialysis programme in Europe. Sandip is an international key opinion leader and expert advisor to scientific community and global industry leaders in dialysis, National Horizons Scanning Centre and Department of Public Health. Recently recognized as one of the Top 50 Healthcare Innovators in the UK.
Leonard is a Consultant Nephrologist and a Deputy Clinical Director for Directorate of Renal Medicine at Manchester Royal Infirmary. In 2012, he completed his PhD at the University of Manchester titled “Extraction and Analysis of Interstitial Fluid and Characterisation of the Interstitial Compartment in Kidney Disease” was recognised as outstanding and he won The Postgraduate Student of the Year Distinguished Awards Medal. For his interstitial fluid extraction work he gained further recognition by winning prizes such as the Young Innovator Award at the American Society of Artificial Internal Organs and the European Renal Association Fellowship award. Leonard leads ongoing research in the area of interstitial fluid extraction.
Renephra Ltd. will be open for investment soon.
Make a reservation with no compromise, just enter the amount you would like to invest.
If you’re interested in joining this round, please tell us how much you’d like to invest, then click “I AM INTERESTED”
Once the campaign is live, you will have 5 days to formalise your investment and make the payment; until then you are free to cancel this reservation at any time
If you choose to continue to make this pledged investment when the campaign opens, you should be aware that your capital would be at risk. Please read our Risk Warning for further details of the risks involved with early stage investing.